The efficacy of HAIC in combination with sorafenib: multicenter, phase II study

The efficacy of HAIC in combination with sorafenib: multicenter, phase II study - The efficacy of HAIC in combination with sorafenib.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015739

Enrollment

Registered

2014-11-22

Start date

2014-11-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Sorafenib is administered orally 400 mg(2 x 200 mg) once or twice daily.The regimen of HAIC contains platinum,fluorouracil,epirubicin or mitomycin C. HAIC is repeated every 4 to 6 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with advanced hepatocellular carcinoma who has already administerd sorafenib at least 4 weeks.

Exclusion criteria

Exclusion criteria: Patients with large volume ascites, brain metastases, hypertension (diastric pressure is over 100mmHg), uncontrorable cardiac problems, sever renal failure, active infection (without viral hepatitis), active gastric bleeding, cancer in other organ, hepatic encepharopathy, and sever drug allergy. Pregnant or lactating women, and the women who wish to be pregnant. Patients who have difficulty in oral feeding.

Design outcomes

Primary

Measure	Time frame
Adverse effect, QOL, response rate, PFS, OS	—

Countries

Japan

Contacts

Public ContactTakaaki Sugihara

Tottori University Faculty of Medicine Department of gastroenterology

sugitaka@med.tottori-u.ac.jp0859-38-6527

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026